FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia

BMC Blood Disorders

Volumn 9, Issue , 2009, Pages

  Loules, Gedeon ^a   Kalala, Fani ^a   Giannakoulas, Nikolaos ^a   Papadakis, Emmanouil ^b   Matsouka, Panagiota ^a   Speletas, Matthaios ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE; STEM CELL FACTOR RECEPTOR;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BONE MARROW BIOPSY; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EARLY DIAGNOSIS; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; EXON; FEMALE; GENE MUTATION; GENE REARRANGEMENT; GENETIC ANALYSIS; HUMAN; HYPEREOSINOPHILIC SYNDROME; MALE; MOLECULAR MECHANICS; MORBIDITY; PATHOGENESIS; POLYMERASE CHAIN REACTION; REMISSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SPLENOMEGALY; SYSTEMIC MASTOCYTOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 60849121422     PISSN: None     EISSN: 14712326     Source Type: Journal    
DOI: 10.1186/1471-2326-9-1     Document Type: Article

References (21)

1. Chusid MJ Dale DC West BC Wolff SM The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature Medicine (Baltimore) 1975, 54:1-27 10.1097/00005792-197501000-00001 1090795
2. Cools J Stover EH Wlodarska I Marynen P Gilliland DG The FIP1L1-PDGFRα kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia Curr Opin Hematol 2003, 11(1):51-57 14676627 10.1097/00062752-200401000-00008
3. Wilkins HJ Crane MM Copeland K Williams WV Hypereosinophilic syndrome: An update Am J Hematol 2005, 80:148-157 10.1002/ajh.20423 16184589
4. Fletcher S Bain B Diagnosis and treatment of hypereosinophilic syndromes Curr Opin Hematol 2007, 14:37-42 10.1097/00062752-200701000-00008 17133098
5. Cools J DeAngelo DJ Gotlib J Stover EH Legare PD Cortes J Kutok J Clark J Galinsky I Griffin JD Cross NCP Tefferi A Malone J Alam R Schrier SL Schmid J Rose M Vandenberghe P Verhoef G Boogaerts M Wlodarska I Kantarjian H Marynen P Coutre SE Stone R Gilliland G A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome N Engl J Med 2003, 348:1201-1214 10.1056/NEJMoa025217 12660384
6. Griffin JH Leung J Bruner RJ Caligiuri MA Briesewitz R Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome Proc Natl Acad Sci USA 2003, 100:7830-7835 164673 12808148 10.1073/ pnas.0932698100
7. La Starza R Specchia G Cuneo A Beacci D Nozzoli C Luciano L Aventin A Sambani C Testoni N Foppoli M Invernizzi R Marynen P Martelli MF Mecucci C The hypereosinophilic syndrome: Fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases Haematologica 2005, 90:596-601 15921374
8. Pardanani A Brockman SR Paternoster SF Flynn HC Ketterling RP Lasho TL Ho CL Li CY Dewald GW Tefferi A FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia Blood 2004, 104:3038-3045 10.1182/blood-2004-03-0787 15284118
9. Vandenberghe P Wlodarska I Michaux L Zachee P Boogaerts M Vanstraelen D Herregods MC Van Hoof A Selleslag D Roufosse F Maerevoet M Verhoef G Cools J Gilliland DG Hagemeijer A Marynen P Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias Leukemia 2004, 18:734-742 10.1038/sj.leu.2403313 14973504
10. Klion AD Noel P Akin C Law MA Gilliland DG Cools J Metcalfe DD Nutman TB Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness Blood 2003, 101:4660-4666 10.1182/blood-2003-01-0006 12676775
11. Baccarani M Cilloni D Rondoni M Ottaviani E Messa F Merante S Tiribelli M Buccisano F Testoni N Gottardi E de Vivo A Giugliano E Iacobucci I Paolini S Soverini S Rosti G Rancati F Astolfi C Pane F Saglio G Martinelli G The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRa-positive hypereosinophilic syndrome. Results of a multicenter prospective study Haematologica 2007, 92:1173-1179 10.3324/ haematol.11420 17666373
12. Pardanani A Ketterling RP Li CY Patnaik MM Wolanskyj AP Elliott MA Camoriano JK Butterfield JH Dewald GW Tefferi A FIP1L1-PDGFRA in eosinophilic disorders: Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature Leuk Res 2006, 30:965-970 10.1016/j.leukres.2005.11.011 16406016
13. Helbig G Stella-Holowiecka B Grosicki S Bober G Krawczyk M Wojnar J Reiter A Hochhaus A Holowiecki J The results of imatinib therapy for patients with primary eosinophilic disorders Eur J Haematol 2006, 76:535-536 10.1111/j.1600-0609.2006.00652.x 16608506
14. Pardanani A Ketterling RP Brockman SR Flynn HC Paternoster SF Shearer BM Reeder TL Li CY Cross NCP Cools J Gilliland DG Dewald GW Tefferi A CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy Blood 2003, 102:3093-3096 10.1182/ blood-2003-05-1627 12842979
15. Speletas M Kioumi A Loules G Hytiroglou P Tsitouridis J Christakis J Germenis AE Analysis of SLC40A1 gene at the mRNA level reveals rapidly the causative mutations in patients with hereditary hemochromatosis type IV Blood Cells Mol Dis 2008, 40(3):353-359 17997113 10.1016/ j.bcmd.2007.09.011
16. Sotlar K Marafioti T Griesser H Theil J Aepinus C Jaussi R Stein H Valent P Horny HP Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia Mol Pathol 2000, 53(4):188-193 11040941 1186968 10.1136/mp.53.4.188
17. Dahabreh IJ Giannouli S Zoi C Zoi K Voulgarelis M Moutsopoulos HM Management of hypereosinophilic syndrome. A prospective study in the era of molecular genetics Medicine (Baltimore) 2007, 86:344-354 18004179
18. Klion AD Recent advances in the diagnosis and treatment of hypereosinophilic syndromes Hematology Am Soc Hematol Educ Program 2005:209-214 16304382
19. Stover EH Chen J Folens C Lee BH Mentens N Marynen P Williams IR Gilliland DG Cools J Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent Proc Natl Acad Sci USA 2006, 103:8078-83 1472432 16690743 10.1073/ pnas.0601192103
20. Gotlib J Cools J Malone JM Schrier SL Gilliland DG Coutre SE The FIP1L1-PDGFRa fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: Implications for diagnosis, classification, and management Blood 2004, 103:2879-2891 10.1182/ blood-2003-06-1824 15070659
21. Valent P Akin C Metcalfe DD FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis Eur J Clin Invest 2007, 37:153-154 10.1111/j.1365-2362.2007.01757.x 17217382